跳至主要内容
临床试验/DRKS00028158
DRKS00028158已完成未知

Evaluation of SARS-CoV2-specific serum parameters in blood samples of hospitalized COVID-19 patients with acute disease and recovered COVID-19 patients with asymptomatic disease (HTXCOV-01K) - COVIAS_K

Heidelberg ImmunoTherapeutics GmbH0 个研究点目标入组 16 人开始时间: 2022年2月21日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
16

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
N/a: Single Arm Study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • 1. Existence of consent to participate in the study.
  • 2. The patient is at least 18 years old and capable of giving consent. In the case of patients of legal age who are unable to give their consent, consent can be given by a legal guardian.
  • 3. Detection of at least one-time positive SARS-CoV-2 swab PCR test or antibody test for COVID-19.
  • 4. Acute hospitalized due to COVID-19 pneumonia OR recovered with an asymptomatic course.
  • 5. After prior consultation with the sponsor, patients who have received at least one vaccination against the SARS-CoV-2 virus may also be included.

排除标准

  • 1. Any illness or condition that does not medically permit the blood sample in the opinion of the consenting physician.

研究者

相似试验